Background {#Sec1}
==========

Diabetes mellitus (DM) is a set of metabolic disorders characterized by hyperglycemia resulting from defects in insulin secretion and/or action. The prevalence of the disease, which is becoming a major world-wide health problem, is increasing rapidly \[[@CR1]\]. In 2013, 382 million cases of DM worldwide were estimated, and that number is expected to increase to 592 million cases in 2035 \[[@CR1]\]. Diabetes mellitus is associated with microvascular and macrovascular complications, including diabetic nephropathy (DN), a primary cause of end-stage renal disease (ESRD) \[[@CR2]\]. Due to the global increase in prevalence of diabetes there has been a concomitant rise in the number of patients with diabetic nephropathy (DN) indicating a prevalence of 30-40% of the patients with type 1 (T1DM) and type 2 diabetes (T2DM) being affected \[[@CR3]\].

Mostly, individuals with long durations of diabetes and poor glycemic control develop progressive diabetic nephropathy. However, some patients appear to be at increased risk while others remain relatively protected \[[@CR4]\]. Genetic predisposition plays an important role in the risk to developing diabetic nephropathy though the incidence and severity is affected by the extent of control of the abnormal metabolic state associated with diabetes mellitus \[[@CR5]\].

In recent years, there has been an increased understanding of the genetic and molecular basis of development and progression of diabetic nephropathy. Although diabetic nephropathy is traditionally considered a nonimmune disease, recent findings indicate a significant role of immune-mediated inflammatory processes in the pathophysiology of diabetic nephropathy. These include the up-regulation of inflammatory mediators, higher urinary levels of monocyte chemoattractant protein-1 and increasing macrophage influx with the progression of diabetic nephropathy \[[@CR6]--[@CR8]\]. In streptozotocin (STZ) diabetic rats, an increase in glomeruli capillaries area was observed in comparison to normal age-matched controls, implying a pronounced angiogenic reaction to the diabetic condition \[[@CR9]\]. Higher concentration of angiogenic markers, vascular endothelial growth factor (*VEGF*) and transforming growth factor β (*TGF β*) in plasma and urine of diabetic nephropathy patients, emphasize the role of angiogenesis \[[@CR10],[@CR11]\]. Chen and Ziyadeh, \[[@CR12]\] reported attenuation of diabetic albuminaria by blockade of *VEGF* signaling pathway. Further, a recent study showed anti-angiogenic and anti-inflammatory DNA vaccination ameliorates the progression of glomerular pathology in an animal model of diabetic nephropathy \[[@CR13]\]. As inflammation and angiogenesis play a crucial role in the pathomechanism of diabetic nephropathy, many studies have investigated the association of genetic polymorphism in these pathway genes with the risk of diabetic nephropathy. However, there is a lack of consistency among the reported studies due to small sample size, limited power and sparseness of data. Therefore, the aim of this meta-analysis is to analyze all published studies that investigated the association of genetic variants involved in inflammatory cytokines and angiogenesis with diabetic nephropathy and to assess their role in different biochemical pathways.

Methods {#Sec2}
=======

Literature search strategy {#Sec3}
--------------------------

The articles relevant to this study were searched from PubMed, Embase and Cochrane Library in June, 2013. Different possible variations and combinations of the following search terms were used: 'diabetes mellitus', 'diabetic nephropathy', 'ESRD', 'inflammatory cytokines', 'angiogenesis', 'genetic variants', 'polymorphism', 'SNPs' and 'gene'. Additional search query was used by combining the names of the specific genes and genetic variants with the term 'diabetic nephropathy'. The reference list of each relevant publication was also examined to identify additional studies appropriate for inclusion in the meta-analysis. In the initial search no filter for language preference was used.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Only those studies were included in which the cases had diabetes mellitus with macroalbuminuria, overt proteinuria, ESRD due to diabetic nephropathy or diabetic nephropathy identified by biopsy and controls had diabetic mellitus with normoalbuminaria after \> 10 years of diabetes duration. Cases with macroalbuminaria and/or overt proteinuria and/or ESRD were merged together for comparison with controls. The selected studies should provide detailed genotypic data of the genes in the inflammatory and angiogenic pathways. Only articles in English language were included. The cases and controls in the studies included were matched by duration of diabetes and/or age. Lack of information related to the distribution of genotypes or alleles within the case and control groups is one of our exclusion criteria. Studies in which the controls were non-diabetic and/or there was comparison of different stages of diabetic nephropathy were excluded. Review and meta-analysis articles were excluded.

Data extraction and Statistical analysis {#Sec5}
----------------------------------------

Following information was extracted from each selected study like PMID No, first author's surname, journal & year of publication, sample size, ethnicity, methodology, type and duration of diabetes, criteria for diabetic nephropathy and frequency of alleles.

For each SNP, the allelic data from different studies was pooled and minor allele frequencies were calculated and compared between cases and controls. Data were entered into a database and a statistical analysis was performed using SPSS (version 17.0; SPSS, Chicago, IL). The pooled odds ratio was used to estimate the association between the genetic variants and diabetic nephropathy in this meta-analysis. The Odds Ratio (OR), at allele level and statistically significant P-values were validated for all the studies and recalculated for some of them, in order to remove any adjustments made within each study in cases where two different groups merged together, such as in the case of macroalbuminaria and ESRD groups. A p-value \<0.05 was considered to be statistically significant. Deviation from Hardy--Weinberg equilibrium (HWE) was tested using the De Finetti program (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) for all the studies. The percentage of variation across studies due to heterogeneity rather than chance was estimated via Higgins I^2^ statistics using Comprehensive Meta Analysis Version 2.0 software (Biostat, Englewood NJ, 2005)^.^ I^2^ is estimated by the ratio (Q-df)/Q, where Q is the Cochran's Q statistic and df is degrees of freedom. I^2^ lies between 0 and 100% with values over 50% indicating high heterogeneity \[[@CR14]\]. The random-effects model was performed using Comprehensive Meta Analysis Version 2.0 software. The random effects model assumes that there is a different underlying effect size for each study. Random effects model takes into account the diversity between the studies and is preferred in majority of genetic association studies. Random effects model is generally used in the presence or anticipation of any heterogeneity between studies \[[@CR15]\]. The sub-group analysis was performed for diabetes mellitus type (type 1 or type 2), diabetic nephropathy stage (established diabetic nephropathy or advanced diabetic nephropathy) and ethnicity (European or Asian origin). The genes showing association with diabetic nephropathy were used as input core data for Genomatix Pathway Analysis (Genomatix, Munich, Germany).

Results {#Sec6}
=======

The initial literature search yielded 751 citations with 111 involving inflammatory cytokines and angiogenesis related to diabetic nephropathy in humans. 25 research articles representing 34 different studies were selected after exclusion of studies which included progression of nephropathy, meta-analysis, reviews etc. The selected 34 studies contained 55 genetic variants in 18 genes of inflammatory cytokines and angiogenesis which were associated with diabetic nephropathy. Table [1](#Tab1){ref-type="table"} includes the details and references of all the studies used in this meta-analysis. The detailed information of the studied SNPs and the corresponding pooled odds ratios and p-values are presented in Additional file [1](#MOESM1){ref-type="media"}a, b, c, d and e.Table 1**Details of the genes and studies in this meta-analysis studyGeneSNPArticleNo. of studiesPopulationCase definitionT1D/T2DOR** ^**a**^CCR5 (Chemokine Receptor 5)rs7637813Pettigrew et al, \[[@CR16]\]1IrishEDN^b^11.173(0.932-1.478)10577983Pettigrew et al, \[[@CR16]\]11.163(0.935-1.447)rs2227010Pettigrew et al, \[[@CR16]\]11.0(0.805-1.248)rs17765882Pettigrew et al, \[[@CR16]\]11.501(0.980-2.298)rs2734648Tregouet et al, \[[@CR17]\]3DanishEDN10.969(0.788-1.191)Tregouet et al, \[[@CR17]\]FinnishEDN11.186(0.947-1.486)Tregouet et al, \[[@CR17]\]FrenchEDN11.082(0.853-1.373)Del 32/rs333Ahluwalia et al, \[[@CR18]\]4North IndianEDN22.58 (1.98--3.37)Ahluwalia et al, \[[@CR18]\]South IndianEDN20.88 (0.51--1.5)Pettigrew et al, \[[@CR16]\]IrishEDN11.242(0.859-1.794)Mlynarski et al, \[[@CR19]\]AmericanADN^c^10.959(0 .652 1.410)59029 G.A/rs1799987Pettigrew et al, \[[@CR16]\]10IrishEDN11.017(0.818-1.263)Ahluwalia et al, \[[@CR18]\]North IndianEDN22.22 (1.71--2.87)Ahluwalia et al, \[[@CR18]\]South IndianEDN22.17 (1.43--3.29)Buraczynska et al, \[[@CR20]\]PolishEDN21.83(1.43-2.34)Mlynarski et al, \[[@CR19]\]AmericanADN10.904(0.664- 1.23)Nakajima et al, \[[@CR21]\]JapaneseEDN21.179(0.855-1.627)Tregouet et al, \[[@CR17]\]DanishEDN11.112(0.918-1.348)Tregouet et al, \[[@CR17]\]FinnishEDN11.152(0.938-1.415)Tregouet et al, \[[@CR17]\]FrenchEDN11.063(0.845-1.336)Prasad et al, \[[@CR22]\]IndianADN21.379(1.047-1.818)ADIPOQ (Adiponectin, C1Q And Collagen Domain Containing)rs266729Zhang et al, \[[@CR23]\]2EuropeanEDN + ADN11.120(0.929-1.35)Wu et al, \[[@CR24]\]TaiwaneseEDN21.39(1.0-1.9)rs17300539Vionnet et al, \[[@CR25]\]4DanishEDN and Ret^d^11.348(0.965-1.884)Vionnet et al, \[[@CR25]\]FinnishEDN and Ret11(0.570-1.754)Vionnet et al, \[[@CR25]\]FrenchEDN and Ret11.472(0.998-2.171)Prior et al, \[[@CR26]\]BritishEDN and Ret11.924 (1.024-3.617)IL8 (Interleukin-8)rs4073Ahluwalia et al, \[[@CR18]\]2North IndianEDN21.44 (1.1--1.88)Ahluwalia et al, \[[@CR18]\]South IndianEDN21.5 (0.96--2.33)CCL2 (Chemokine ligand 2)rs1024611Ahluwalia et al, \[[@CR18]\]2North IndianEDN21.04 (0.8--1.36)Joo et al, \[[@CR27]\]KoreanADN20.91(0.65-1.2)rs3917887Ahluwalia et al, \[[@CR18]\]2North IndianEDN22.03 (1.57--2.63)Ahluwalia et al, \[[@CR18]\]South IndianEDN21.7 (1.12--2.57)MMP9 (Matrix Metallopeptidase 9)rs17576Ahluwalia et al, \[[@CR18]\]2North IndianEDN21.81 (1.40--2.34)Ahluwalia et al, \[[@CR18]\]South IndianEDN22.19 (2.45--3.31)IL-10 (Interleukin-10)--592C/A/rs1800872Arababadi et al, \[[@CR28]\]2IranianEDN21.484(0.944-2.331)Ezzidi et al, \[[@CR2]\]/ Mtiraoui et al, \[[@CR29]\]TunisianEDN20.915(0.751-1.114)--819C/T/rs1800871Ezzidi et al, \[[@CR2]\]/ Mtiraoui et al, \[[@CR29]\]10.777(0.631-0.958)--1082G/A/rs1800896Ezzidi et al, \[[@CR2]\]/ Mtiraoui et al, \[[@CR29]\]10.841(0.694-1.018)IL-1 (Interleukin-1)IL1ALoughrey et al, \[[@CR30]\]1CaucasianEDN10.66 (0.42-1.04)IL1BLoughrey et al, \[[@CR30]\]11.971(1.221-3.182)IL1RILoughrey et al, \[[@CR30]\]10.94(0.618-1.429)VEGFA (Vascular endothelial growth factor A)- 2549 I/D/rs35569394Yang et al, \[[@CR31]\]2BritishEDN and Ret11.619(1.038-2.525)Buraczynska et al, \[[@CR32]\]PolishEDN21.09(0.77-1.54)+405/rs2010963Buraczynska et al, \[[@CR32]\]2PolishEDN20.949(0.658-1.369)McKnight et al, \[[@CR33]\]IrishEDN and Ret10.88 (0.69-1.12)-1499C \> T/rs833061McKnight et al, \[[@CR33]\]2IrishEDN and Ret12.08(1.63-2.66)-2578C \> A/rs699947McKnight et al, \[[@CR33]\]2IrishEDN and Ret10.92(0.72-1.17)rs2146323Tregouet et al, \[[@CR17]\]3DanishEDN10.899(0.732-1.105)Tregouet et al, \[[@CR17]\]FinnishEDN10.914(0.739-1.131)Tregouet et al, \[[@CR17]\]FrenchEDN10.854(0.667-1.095)rs3024997Tregouet et al, \[[@CR17]\]3DanishEDN10.967(0.786-1.191)Tregouet et al, \[[@CR17]\]FinnishEDN10.986(0.773-1.257)Tregouet et al, \[[@CR17]\]FrenchEDN11.124(0.879-1.438)rs3025000Tregouet et al, \[[@CR17]\]3DanishEDN10.962(0.781-1.186)Tregouet et al, \[[@CR17]\]FinnishEDN10.974(0.765-1.240)Tregouet et al, \[[@CR17]\]FrenchEDN11.087(0.843-1.402)936C/T/rs3025039Kim et al, \[[@CR34]\]2koreanEDN + ADN21.632(0.984-2.708)VEGFB (Vascular endothelial growth factor B)rs12366035Tregouet et al, \[[@CR17]\]3DanishEDN10.784(0.633-0.971)Tregouet et al, \[[@CR17]\]FinnishEDN10.92(0.727-1.163)Tregouet et al, \[[@CR17]\]FrenchEDN11.144(0.887-1.474)VEGFC (Vascular endothelial growth factor C)rs585706Tregouet et al, \[[@CR17]\]3DanishEDN10.8(0.562-1.139)Tregouet et al, \[[@CR17]\]FinnishEDN11.318(0.917-1.895)Tregouet et al, \[[@CR17]\]FrenchEDN11.271(0.882-1.832)IL-6 (Interleukin-6)rs2069827Ng et al, \[[@CR35]\]1CaucasianEDN + ADN20.65(0.365-1.159)rs1800796Ng et al, \[[@CR35]\]0.935(0.588-1.487)rs1800795Ng et al, \[[@CR35]\]0.829(0.623-1.104)rs2069837Ng et al, \[[@CR35]\]0.865(0.54-1.384)rs2069840Ng et al, \[[@CR35]\]0.916(0.686-1.225)rs2069861Ng et al, \[[@CR35]\]1.505(0.882-2.569)TGF-B1 (Transforming growth factor beta 1)rs1800470Jahromi et al, \[[@CR36]\]8CaucasianEDN11.06(0.64-1.7)Ahluwalia et al, \[[@CR18]\]North IndianEDN21.1 (0.83--1.44)Ng et al, \[[@CR37]\]CaucasianEDN + ADN10.923(0.722--1.180)McKnight et al, \[[@CR33]\]IrishEDN11.2(0.7-2.1)Tregouet et al, \[[@CR17]\]DanishEDN10.979(0.799-1.199)Tregouet et al, \[[@CR17]\]FinnishEDN11.068(0.852-1.338)Tregouet et al, \[[@CR17]\]FrenchEDN11.034(0.816-1.311)Salgado et al, \[[@CR38]\]MexicanEDN + ADN21.30(0.99-1.71)Tyr81His/rs111033611Ahluwalia et al, \[[@CR18]\]1North IndianEDN21.14 (0.53--2.46)915 G \> C/rs1800471Ng et al, \[[@CR37]\]3CaucasianEDN + ADN21.022(0.627--1.665)McKnight et al, \[[@CR33]\]IrishEDN11.0(0.66-1.5)Salgado et al, \[[@CR38]\]MexicanEDN + ADN24.17(1.40-12.3)-800 A \> Grs1800468Ng et al, \[[@CR37]\]4CaucasianEDN + ADN21.178(0.762--1.821)McKnight et al, \[[@CR33]\]IrishEDN10.75(0.45-1.2)Prasad et al, \[[@CR22]\]IndianADN21.04(0.816-1.325)Salgado et al, \[[@CR38]\]MexicanEDN + ADN20.98(0.46-2.09)rs1800469Ng et al, \[[@CR37]\]3CaucasianEDN + ADN21.088(0.841--1.407)McKnight et al, \[[@CR33]\]IrishEDN10.94(0.58-1.5)Prasad et al, \[[@CR22]\]IndianADN20.738(0.50-1.091)rs1800472Ng et al, \[[@CR37]\]1CaucasianEDN + ADN21.168(0.639--2.135)rs2241717Tregouet et al, \[[@CR17]\]3DanishEDN10.957(0.787-1.164)Tregouet et al, \[[@CR17]\]FinnishEDN11.068(0.864-1.322)Tregouet et al, \[[@CR17]\]FrenchEDN10.917(0.729-1.155)rs8179181Tregouet et al, \[[@CR17]\]3DanishEDN11.193(0.957-1.488)Tregouet et al, \[[@CR17]\]FinnishEDN11.022(0.799-1.308)Tregouet et al, \[[@CR17]\]FrenchEDN10.944(0.722-1.234)TGF-BR1 (TGF beta receptor 1)rs1571589Tregouet et al, \[[@CR17]\]3DanishEDN10.951(0.746-1.213)Tregouet et al, \[[@CR17]\]FinnishEDN11.111(0.836-1.476)Tregouet et al, \[[@CR17]\]FrenchEDN11.018(0.766-1.352)rs928180Tregouet et al, \[[@CR17]\]3DanishEDN11.362(0.988-1.877)Tregouet et al, \[[@CR17]\]FinnishEDN10.92(0.67-1.263)Tregouet et al, \[[@CR17]\]FrenchEDN10.901(0.608-1.334)TGF-BR2 (TGF beta receptor 2)747C \> G/rs11466531McKnight et al, \[[@CR33]\]1IrishEDN11.37(1.0-1.89)1149G \> A/ss50394788McKnight et al, \[[@CR33]\]1IrishEDN12.432(0.81-7.303)CCR2 (chemokine receptor type 2)G46295A/rs1799864Joo et al, \[[@CR27]\]koreanADN20.91(0.65-1.2)rs1799865Prasad et al, \[[@CR22]\]1IndianADN21.551(0.901-2.671)RANTES/CCL5 (Chemokine ligand 5)C-28G/rs2280788Joo et al, \[[@CR27]\]2koreanADN20.97(0.65-1.4)Nakajima et al, \[[@CR21]\]JapaneseEDN21.532(1.004-2.338)ss161639200Pettigrew et al, \[[@CR16]\]1irishEDN11.140(0.821-1.584)rs9898132Pettigrew et al, \[[@CR16]\]1IrishEDN11.092(0.746-1.599)G-403A/rs2107538Joo et al, \[[@CR27]\]3KoreanADN20.8(0.59-1.0)Pettigrew et al, \[[@CR16]\]IrishEDN11.085(0.81-1.452)Nakajima et al, \[[@CR21]\]JapaneseEDN20.88(0.632-1.225)EPO (Erythropoietin)rs1617640Tong et al, \[[@CR39]\]3AmericanEDN + ADN21.446(1.145-1.826)Tong et al, \[[@CR39]\]11.535(1.320-1.787)Tong et al, \[[@CR39]\]11.382(1.050-1.820)TNFα (Tumor necrosis factor)-308/rs1800629Prasad et al, \[[@CR22]\]1IndianADN21.383(0.775-2.468)^a^OR, Odds ratio (95% CI); ^b^EDN, established diabetic nephropathy; ^c^ADN, advanced diabetic nephropathy; ^d^Ret, retinopathy.This meta- analysis included 55 SNPs in 18 genes of inflammatory cytokines and angiogenesis which were associated with diabetic nephropathy.

Of the 55 genetic variants involved in the inflammatory cytokines and angiogenesis, 11 genetic variants in or near 9 genes were significantly associated with diabetic nephropathy after random-effects meta-analysis. Figure [1](#Fig1){ref-type="fig"} is a Forest plot representation of the significantly associated genetic variants with diabetic nephropathy- *VEGFA*, *CCR5* (*Chemokine Receptor 5*), *CCL2* (*Chemokine ligand 2*), *IL-1* (*Interleukin-1*), *MMP9* (*Matrix Metallopeptidase 9*), *EPO* (*Erythropoietin*), *IL-8* (*Interleukin-8*), *ADIPOQ* (*Adiponectin, C1Q And Collagen Domain Containing*) and *IL-10* (*Interleukin-1*). The odds ratios of the significant associations with diabetic nephropathy were between the range of 1.24 to 2.08 for increased risk effect. After meta-analysis, 2 genetic variants- rs833061 in the *VEGFA* gene and rs3917887 in the *CCL2* gene showed the most significant association with risk of diabetic nephropathy. Genetic variant rs833061 was analyzed in 2 Irish studies resulting in a pooled odds ratio of 2.08 (95% CI 1.63-2.66). For rs3917887, the pooled OR was 2.04 (95% CI 1.64-2.54) obtained from 2 Indian studies. rs833061 showed significant association in type 2 diabetes mellitus whereas rs3917887 was studied in type 1 diabetes mellitus. Genetic variant rs1799987 in *CCR5* was the most studied SNP with ten studies of which six were of caucasian and four Asian. Five studies involved type 1 diabetes mellitus while the other five included type 2 diabetes mellitus resulting in a pooled odds ratio of 1.29 (95% CI 1.20-1.38). Figures [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} show the association of variants with diabetic nephropathy among sub-groups. The significant association between rs1799987 and diabetic nephropathy was reproduced in type 2 diabetes mellitus, Asian, Caucasian and established diabetic nephropathy subgroups. This association was not significant in the type 1 diabetes mellitus and advanced diabetic nephropathy subgroups. Other significantly associated genetic variant, rs333 (Del32) in the *CCR5* gene had a pooled odds ratio of 1.24 (95% CI 1.08-1.43) from four studies. Among these four studies, two Asian studies involved type 2 diabetes mellitus whereas two Caucasian studies were for type 1 diabetes mellitus. The association was reproduced in the subgroup analysis (Figure [2](#Fig2){ref-type="fig"}).Figure 1**Forest Plot for genetic variants involved in inflammatory cytokines and angiogenesis and significantly associated with diabetic nephropathy after meta-analysis.**Figure 2**Genetic variants significantly associated with diabetic nephropathy after meta-analysis in a subgroup; T1D- type 1 diabetes mellitus, T2D- type 2 diabetes mellitus, Cau-Caucasian origin, EDN- established diabetic nephropathy.**Figure 3**Genetic variants not significantly associated with diabetic nephropathy after meta-analysis in a subgroup; T1D- type 1 diabetes mellitus, T2D- type 2 diabetes mellitus, EDN- established diabetic nephropathy, ADN- advanced diabetic nephropathy.**

The genetic variant rs17300539 in *ADIPOQ* gene was studied in four european studies, all involving type 1 diabetes mellitus. rs17300539 was significantly associated with diabetic nephropathy with a pooled odds ratio of 1.35 (95% CI 1.09-1.68). rs4073 SNP in IL-8 gene had a pooled OR of 1.45 (95% CI 1.16-1.82) from two Indian studies involving type 2 diabetes mellitus. In the same Indian studies, another genetic variant rs17576 in the *MMP9* gene was significantly associated with diabetic nephropathy with a pooled OR of 1.91 (95% CI 1.54-2.38). The genetic variant rs3025039 in the *VEGF* gene was found to be significantly associated with diabetic nephropathy with a pooled OR of 1.63 (95% CI 0.98-2.70). Two studies in the Korean population investigated rs3025039 in type 2 diabetic patients. The genetic variant rs1617640 in the *EPO* gene was investigated in three American studies in which one study included type 2 diabetes mellitus whereas other two were for type 1 diabetes mellitus. After meta-analysis, the pooled OR of 1.47 (95% CI 1.31-1.65) showed a significant association with diabetic nephropathy. There was only one study in type 1 diabetes Caucasian population for the SNP IL1B in the *IL-1* gene. IL1B showed a significant association with risk of diabetic nephropathy having an OR of 1.97 (95% CI 1.22-3.18).

In this meta-analysis, there was only one SNP which had a protective effect against diabetic nephropathy. Genetic variant rs1800871 in the *IL-10* gene was studied in a Tunisian study and had an OR of 0.77 (95% CI 0.63-0.98). In our meta-analysis, there were 44 genetic variants in the genes involved in inflammatory cytokines and angiogenesis that were not found to be significantly associated with DN (Figure [4](#Fig4){ref-type="fig"}). It is important to mention that among the 44 SNPs, only 22 were investigated in two or more than two studies while the others had a single study each. Genetic variant rs1800470 showed a significant association with diabetic nephropathy in the type 2 diabetes mellitus subgroup with an OR of 1.25 (95% CI 1.04-1.51) (Figure [2](#Fig2){ref-type="fig"}).Figure 4**Forest Plot for genetic variants involved in inflammatory cytokines and angiogenesis and not significantly associated with diabetic nephropathy after meta-analysis.**

For this meta-analysis, genes showing significant association with diabetic nephropathy were analyzed to assess their contribution in different functional pathways. G protein coupled-receptors (GPCRs) or seven-transmemebrane receptors are the most prevailing class of signaling transduction molecules in humans. In the GPCR signaling pathways, inflammatory cytokine and angiogenic genes positively associated with diabetic nephropathy encode proteins present on the extra-cellular membrane. Among the nine genes showing significant association with diabetic nephropathy in our study- *IL10*, *VEGFA*, *EPO*, *IL1* and *IL8* were a part of GPCR signaling pathway (Figure [5](#Fig5){ref-type="fig"}). In the molecular function based pathway, *VEGFA*, *EPO*, *IL1*, *IL8*, *IL10*, *ADIPOQ* and *CCL2* were involved in receptor binding. *EPO* and *ADIPOQ* are inhibited by TNF (Tumor necrosis factor) , whereas, other genes are activated by TNF. *VEGFA* is activated by SMAD3 (Mothers against decapentaplegic homolog 3) present in the intra-cellular region (Figure [6](#Fig6){ref-type="fig"}). Disease pathway analysis showed *IL6*, *EPO*, *ADIPOQ* and *CCR2* to be involved in chronic kidney failure. The hierarchical layout shows that *IL6*, *EPO*, *ADIPOQ* and *CCR2* function by influencing *angiotensin I-converting enzyme* (*ACE*) gene expression. *ACE* further interacts with G-protein beta3-subunit (GNB3) and this interaction is also associated with hypertension in many populations (Figure [7](#Fig7){ref-type="fig"}).Figure 5**Genes involved in GPCR signaling Pathway: (G protein coupled-receptors are seven-transmemebrane receptors involved in signal transduction in humans).**Figure 6**Genes involved in receptor binding pathway.**Figure 7**Genes involved in chronic kidney failure (Disease Pathway).**

Publication Bias {#Sec7}
----------------

Thirty six genetic variants were lacking a good number of studies (i.e. less than three studies), thus it was not possible to calculate the publication bias. Of the other nineteen studies, six SNP studies (ADIPOQ rs17300539; RANTES rs2107538; TGF-B1 rs1800468; TGF-B1 rs2241717; VEGFA rs3024997; VEGFA rs3025000) did not account for publication bias as evident from the symmetric funnel plot and thirteen did show evidence of publication bias (Additional file [2](#MOESM2){ref-type="media"}).

Discussion {#Sec8}
==========

This meta-analysis, including 55 genetic variants in 18 genes from 34 published studies, explored the association between the genetic variants within the genes involved in inflammatory cytokines and angiogenesis pathways and diabetic nephropathy. The results showed that 11 genetic variants were significantly associated with diabetic nephropathy.

Cytokines act as pleiotropic polypeptides regulating inflammatory and immune responses through actions on cells. The relationships between inflammation and the development and progression of diabetic nephropathy involve complex molecular networks and processes. Many studies have shown a strong association of circulating inflammatory markers and proinflammatory cytokines with the risk of developing of diabetic complications \[[@CR40]\]. Evidence from studies where immunosuppressive strategies reduce renal macrophage accumulation and attenuate the development of diabetic nephropathy, support the role of inflammation in diabetic complications \[[@CR40]\].

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, has been implicated in the genesis of diverse diabetic complications including diabetic nephropathy. Several studies have reported an increase in potent stimulators of angiogenesis in diabetic nephropathy \[[@CR41],[@CR42]\]. In addition, the therapeutic efficacies of anti--angiogenic strategies have further demonstrated the involvement of angiogenesis in the progression of diabetic nephropathy \[[@CR13],[@CR43]\]. In this context, genetics of inflammatory cytokines and angiogenesis is important to analyze the involved genes and their role in susceptibility to diabetic nephropathy.

In this meta-analysis, variants within or near *VEGFA* (two variants), *CCR5* (two variants), *CCL2*, *IL-1*, *MMP9*, *EPO*, *IL-8*, *ADIPOQ* and *IL-10* were significantly associated with diabetic nephropathy. Three genetic variants (two in the *VEGFA* and one in the *EPO* gene) belonged to angiogenesis pathway whereas the other variants were included in inflammatory cytokines. These results support a role of the inflammatory cytokines and angiogenesis pathways in the pathogenesis of diabetic nephropathy.

It has been reported that there is an increased *VEGF* expression in patients with diabetic nephropathy and antibodies against *VEGF* in the early stages of experimental diabetes can ameliorate the renal dysfunction \[[@CR31]\]. In this meta-analysis, two genetic variants in *VEGFA* gene were significantly associated with diabetic nephropathy. Both genetic variants were analysed in studies with moderate sample size. and more studies are needed to establish true effect sizes in such cases \[[@CR44]\]. T allele of rs833061 genetic variant in *VEGFA* gene was found to increase the risk of diabetic nephropathy whereas Mooyaart et al. \[[@CR44]\] in their study considered C allele of rs833061 as having a protective effect.

*CCL2*, also known as *Monocyte chemo-attractant protein-1*(*MCP-1*), is the strongest known chemo-tactic factor for monocytes and is upregulated in diabetic nephropathy \[[@CR18]\]. In this meta-analysis, the insertion at *CCL2* rs3917887 showed two fold higher risk of diabetic nephropathy as compared to controls. Chinoy et al. have reported the association *CCL2* rs3917887 with development of inflammatory myopathies \[[@CR45]\].

*CCR5* is a β-chemokine receptor involved in a migration of monocytes, NK cells and some T-cells to the inflammation site \[[@CR20]\]. *CCR5* rs1799987 was the most studied genetic variant in inflammatory cytokines. This SNP is reported to increase the protein level by increasing the transcriptional activity of the *CCR5* gene \[[@CR46]\]. Also, for genetic variant rs1799987 in *CCR5* gene A allele was the risk factor for diabetic nephropathy in our study whereas Mooyaart et al. \[[@CR44]\] considered G allele of rs1799987 as a protective allele. The 32 --bp deletion in *CCR5* rs333 changes the open reading frame of the gene resulting in a trunacated protein \[[@CR47]\]. This polymorphism showing a significant association with DN in this meta-analysis, is shown to promote renal fibrosis instead of normal tissue repair \[[@CR48]\].

*ADIPOQ* encodes adiponectin, a hormone exclusively secreted by the adipose tissue \[[@CR23]\]. A allele of rs17300539 in the promoter of *ADIPOQ* is a risk factor for DN. It has been suggested that this genetic variation may contribute to an increased risk of developing nephropathy partly through the increase in adiponectin levels \[[@CR25]\].

*IL-8* is a member of the CXC chemokine family and is associated with a variety of proinflammatory activities \[[@CR49]\]. rs4073 lies in the regulatory region and increases the protein level. An increase in the urinary excretion of *IL-8* in DN patients has been reported \[[@CR18]\]. In their study, Skov et al., showed that *IL-8* is an antibody therapeutic target in inflammatory diseases \[[@CR49]\].

The pro-inflammatory cytokine interleukin 1 (IL-1) stimulates kidney mesangial cell proliferation and extracellular matrix expansion, contributing to pathogenesis of DN \[[@CR30]\]. In this meta-analysis, there is only one study showing allele IL1B\*2 associated with a nearly two fold higher risk of diabetic nephropathy. Additional studies are required to establish the reported risk factor.

*MMP9* rs17576 lies in the substrate binding region and leads to over-accumulation of extracellular matrix, leading to renal damage \[[@CR18]\]. Rysz et al. reported an increase in MMP-9 in diabetic nephropathy when compared with diabetes with normal renal function \[[@CR50]\].

EPO is a potent angiogenic factor involved in diabetic micro-vascular complications \[[@CR39]\]. Garcia et al. reported EPO increased the rate of renal damage \[[@CR51]\]. T allele of genetic variant rs1617640 in *EPO* gene was a risk allele for diabetic nephropathy in this meta-analysis. This finding was in agreement with Williams et al. \[[@CR52]\] who in their study showed T allele of rs1617640 as a risk factor for diabetic nephropathy. On the contrary, Mooyaart et al. \[[@CR44]\] considered T allele to have a protective effect for diabetic nephropathy.

Interleukin-10 (IL-10) fulfils the criteria for an anti-inflammatory and immunosuppressive cytokine \[[@CR53]\]. Wong et al. reported a correlation between IL-10 levels and extent of renal damage in diabetic nephropathy \[[@CR54]\]. There were two studies investigating the protective effect of T allele of rs1800871 for diabetic nephropathy. Both the studies were done in Tunisian population by the same authors with apparently the same study group (Table [1](#Tab1){ref-type="table"}- ref. 2, 29). Since the methodology and results were identical for the two studies, we considered them as a single study to avoid overestimation of effects.

An important factor that bears on the interpretation of meta-analysis of the genetics of diabetic nephropathy is the adequacy of phenotype definition. This problem is reflected in studies showing that most patients with type 1 diabetes categorized initially as having microalbuminaria, undergo regression to normoalbuminaria \[[@CR52]\]. To avoid this problem in our meta-analysis, we only included studies where diabetic nephropathy was defined by macroalbuminaria or ESRD. As with all meta-analysis, one major limitation of this study is publication bias. Only published data in journals was included in this study which may lead to ignoring the negative or non-significant association studies. Heterogeneity between the studies can affect the interpretation of results. One of the potential reason for heterogeneity is the winner's curse, which appears as an upward bias in the estimated effect of a newly identified allele on disease risk when the study design lacks sufficient statistical power. . The winner's curse manifests mostly in genome‐wide association (GWA) studies in which 300 000--1 000 000 single‐nucleotide polymorphisms are tested \[[@CR55]\]. All the studies included in this meta-analysis were candidate gene based. Further, to minimize the overestimation caused by the winner's curse, effect sizes and minor allele frequencies were calculated from pooled estimates from the initial reporting study and other subsequent studies. Random effects model was performed to account for any possible heterogeneity.

In this study, enrichment analysis of the genes significantly associated with diabetic nephropathy, generated three functional pathways- GPCR signaling, receptor binding and chronic kidney failure. GPCRs transduce extracellular signals inside the cell through activation of heterotrimeric G proteins and/or via other G protein-independent signaling pathways. Agonist-induced GPCR phosphorylation by G protein-coupled receptor kinases (GRKs) are involved in a number of important systems related to the development and progression of Diabetic nephropathy \[[@CR56]\]. Presence of these genes in the functional pathways supports their significant association with diabetic nephropathy as concluded in this meta-analysis. However, further experiments are required to elucidate the exact role of these genes in the pathogenesis of diabetic nephropathy.

Considering a worldwide increase in diabetes, there is an urgent need to provide patients protection from the development and progression of diabetic nephropathy. Identification of genes involved in the primary mechanisms contributing to onset and progression of diabetic nephropathy is important for developing new therapeutic interventions. Inflammatory cytokines and angiogenic factors play a diverse role in the pathogenesis of diabetic nephropathy. The recognition of the genes/genetic variants as having a significant association with risk of diabetic nephropathy will provide new therapeutic targets. Furthermore, this will also help to identify patients with increased risk of diabetic nephropathy.

Conclusions {#Sec9}
===========

This study identified 11 genetic variants in or near 9 genes -*VEGFA*, *CCR5*, *CCL2*, *IL-1*, *MMP9*, *EPO*, *IL-8*, *ADIPOQ* and *IL-10*, significantly associated with diabetic nephropathy. Further studies are required to better understand their functional relevance in the pathogenesis of diabetic nephropathy. These genetic variants within the inflammatory cytokines and angiogensis pathways might be good candidates for identifying genetic predisposition to DN as well as revealing the pathogenesis of diabetic nephropathy.
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